Efficacy and Safety of Etelcalcetide in Hemodialysis Patients with Moderate to Severe Secondary Hyperparathyroidism

• Autori principali: Paola Monciino (Autore), Lorenza Magagnoli (Autore), Eliana Fasulo (Autore), Michela Frittoli (Autore), Chiara Leotta (Autore), Hoang Nhat Pham (Autore), Andrea Stucchi (Autore), Paola Ciceri (Autore), Andrea Galassi (Autore), Mario Cozzolino (Autore)
• Natura: Libro
• Pubblicazione: MDPI AG, 2022-09-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

Background. Secondary hyperparathyroidism (SHPT) is a major risk factor for cardiovascular events and all-cause mortality in hemodialysis (HD) patients. The purpose of our study was to evaluate the effects and tolerability of etelcalcetide in HD patients with SHPT. Methods. An observational study wa...